Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03222973
Recruitment Status : Active, not recruiting
First Posted : July 19, 2017
Last Update Posted : September 25, 2020
Sponsor:
Information provided by (Responsible Party):
Biogen

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 3, 2022
Estimated Study Completion Date : May 26, 2022